Treatment for multiple types of cancer! Roche (RHHBY.US) PD-L1 monoclonal antibody subcutaneous formulation treatment only takes 7 minutes.

Roche (RHHBY.US) announced that its targeted PD-L1 antibody Tecentriq Hybreza (atezolizumab and hyaluronidase) subcutaneous formulation has been approved by the US FDA for the treatment of all adult indications approved for Tecentriq intravenous injection, including certain types of lung cancer, liver cancer, skin cancer, and soft tissue cancer. According to the press release, Tecentriq Hybreza is the first FDA-approved PD-1/PD-L1 inhibitor subcutaneous injection therapy. Compared to traditional intravenous infusion which takes 30-60 minutes, Tecentriq Hybreza subcutaneous injection only takes about 7 minutes, providing patients with a more convenient treatment option. Tecentriq is a targeted PD-L1 monoclonal antibody developed by Roche. PD-L1 is a protein expressed on tumor cells and tumor-infiltrating immune cells. By inhibiting PD-L1, Tecentriq can activate T cells to achieve therapeutic effects on tumors. Currently, the drug has been approved globally for the treatment of various cancers including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma, urothelial carcinoma, PD-L1-positive metastatic triple-negative breast cancer, and BRAF V600 mutation-positive advanced melanoma.